Mental Health & Behavioral Research, Phase COVID-II

Mechanistic Evaluation of Guanfacine on Drinking Behavior

Volunteers
Health Professionals

What is the purpose of this trial?

In this study, we are seeking individuals who are interested in reducing or cutting back their drinking behavior. We will be looking at how the medication Intuniv, which is Guanfacine, influences drinking behavior. Guanfacine is a medication that has been approved by the Food and Drug Administration (FDA) to treat high blood pressure and ADHD. There are three phases to the study.

Trial with
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Ages
21 years - 70 years
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Meaghan Lavery

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Sherry McKee, PhD
Professor of Psychiatry; Director, Yale Behavioral Pharmacology Laboratory; Clinical Director, Forensic Drug Diversion Clinic; Director, Yale Program for Sex Differences in Alcohol Use Disorder, Psychiatry

Sub-Investigators

Last Updated
10/17/2024
Study HIC
#2000023970